fig3

Figure 3. Therapeutic efficacy of GSK3β inhibitors (AR-A014418 and SB-216763) against human osteosarcoma cell orthograft tumors in the knee joints of mice^[46] (left panels) and schematic representation of the hypothetical triple benefits of GSK3β inhibitors: anti-tumor effect, reduction of post-surgery tissue defect, and bone preservation (right panels). Dotted lines in the middle two panels indicate the area of orthograft tumors. GSK3β: glycogen synthase kinase 3β; DMSO: dimethyl sulfoxide (diluent for GSK3β inhibitors)